Vaxart, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Vaxart, Inc. (VXRT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.59 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-06
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $0.59, a 28.26% increase year-over-year.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $0.46, a 55.77% decline year-over-year.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $1.04, a 33.33% increase year-over-year.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $0.78, a 82.59% decline year-over-year.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $0.78, a 79.90% decline from fiscal 2022.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $3.88.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2017 was $0.47, a 62.70% decline from fiscal 2016.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2016 was $1.26, a 23.64% decline from fiscal 2015.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.59 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $0.59 S-1 · filed 2026-05-08 | |||
| 2025-12-31 | $0.47 S-1 · filed 2026-05-08 | |||
| 2025-09-30 | $0.47 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $0.47 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $0.46 S-1 · filed 2026-05-08 | |||
| 2024-12-31 | $1.01 S-1 · filed 2026-05-08 | |||
| 2024-09-30 | $1.01 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | $1.01 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | $1.04 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $0.78 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $0.78 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $0.78 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $0.78 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $3.88 10-K · filed 2023-03-15 | |||
| 2022-09-30 | $3.88 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | $3.98 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | $4.48 10-Q · filed 2023-05-04 | |||
| 2021-09-30 | $6.67 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | $6.23 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | $5.46 10-Q · filed 2022-05-09 | |||
| 2019-09-30 | $0.55 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $0.55 10-Q · filed 2019-08-08 | |||
| 2018-09-30 | $3.59 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | $3.59 10-Q · filed 2019-08-08 | |||
| 2017-06-30 | $0.47 10-K · filed 2017-09-01 | |||
| 2017-03-31 | $0.24 10-Q · filed 2017-05-08 | $0.58 10-Q · filed 2017-05-08 | ||
| 2016-09-30 | $0.87 10-Q · filed 2016-11-08 | |||
| 2016-06-30 | $1.26 10-K · filed 2017-09-01 | |||
| 2016-03-31 | $0.88 10-Q · filed 2017-05-08 | $1.34 10-Q · filed 2017-05-08 | ||
| 2015-09-30 | $1.35 10-Q · filed 2016-11-08 | |||
| 2015-06-30 | $1.65 10-K · filed 2016-09-13 | |||
| 2015-03-31 | $1.59 10-Q · filed 2015-05-08 | $1.67 10-Q · filed 2015-05-08 | ||
| 2014-12-31 | $1.68 10-Q · filed 2015-02-06 | $1.67 10-Q · filed 2015-02-06 | ||
| 2014-09-30 | $1.64 10-Q · filed 2015-11-06 | |||
| 2014-06-30 | $2.47 10-K · filed 2016-09-13 | |||
| 2014-03-31 | $4.22 10-Q · filed 2015-05-08 | $3.12 10-Q · filed 2015-05-08 | ||
| 2013-12-31 | $2.78 10-Q · filed 2015-02-06 | $2.75 10-Q · filed 2015-02-06 | ||
| 2013-06-30 | $2.39 10-K · filed 2015-09-11 | |||
| 2013-03-31 | $2.72 10-Q · filed 2014-05-12 | |||
| 2012-12-31 | $2.72 10-Q · filed 2014-02-10 | $2.72 10-Q · filed 2014-02-10 | ||
| 2012-09-30 | $0.96 10-Q · filed 2012-11-08 | |||
| 2012-06-30 | $0.96 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |